Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of induction oxaliplatin + capecitabine + bevacizumab for extensive colorectal peritoneal carcinomatosis
2009-017776-24Phase 2Active
- Start
- Dec 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, capecitabine and bevacizumab in peritoneal carcinomatosis (PC) and colorectal adenocarcinoma. Primary endpoint: Macroscopic and microscopic response to induction chemotherapy. Started Dec 2009; status: active.
02
Drugs
oxaliplatincapecitabinebevacizumab
03
Conditions
peritoneal carcinomatosis (PC)colorectal adenocarcinoma
Beyond the preview
Go deeper on 2009-017776-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017776-24.